

Group A	0	0	1	2	5	2	0	70%
Group B	3**	1	0	2	2	1	1	40%

.*:

Slightly improved or better regarded as responder

** : Withdrawers were graded as "markedly worsened".

Table 3. Change of symptom measures

Variables	Group A (n=10)			Group B (n=7)		
	Baseline	Post-Therapy	P-Value (vs. baseline)	Baseline	Post-therapy	P-Value (vs. baseline)
OSSI	12.6±4.2*	12.4±4.7	0.81	14.9±3.5	11.4±5.0	0.04
OSPI	11.0±3.6	10.2±4.3	0.28	12.0±2.4	10.3±4.5	0.33
NRS	5.4±2.7	4.8±2.3	0.37	6.9±3.2	5.6±3.10	0.41
Daily urinary frequency	15.0±4.1	15.4±4.6	0.59	17.0±5.8	15.7±5.5	0.19
Nocturnal frequency	2.9±1.3	4.0±2.7	0.11	4.0±1.5	4.3±2.4	0.67

*mean±SD

Table 4. Change in symptomatic variables after the therapy.

	Group A (n=10)	Group B (n=7)	P value (A vs. B)
ΔOSSI	-0.2±2.6*	-3.4±3.4	0.04
ΔOSPI	-0.8±2.2	-1.7±4.3	0.57
ΔNRS	-0.6±2.0	-1.3±3.8	0.64
ΔDaily urinary frequency	0.8±2.3	-1.1±2.3	0.16
ΔNocturnal urinary frequency	1.3±1.9	0.3±1.7	0.32

*mean±SD, Δ=(post-therapeutic value) – (base line value)

References

1. Nomiya A., et al. On- and post-treatment symptom relief by repeated instillations of heparin and alkalized lidocaine in interstitial cystitis. *Int J Urol.* 2013. 29; 1118-22
2. Homma Y., et al. Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015. *Int J Urol.* 2016. 23; 542-9

Disclosures

Funding: Iida Grant of Mitsui Memorial Hospital **Clinical Trial:** Yes **Registration Number:** University hospital Medical Information Network center, UMIN000026714 **RCT:** Yes **Subjects:** HUMAN **Ethics Committee:** Mitsui Memorial Hospital Ethics Committee **Helsinki:** Yes **Informed Consent:** Yes